Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Diversion Concerns on the Rise

Kurt Ullman  |  Issue: September 2012  |  September 5, 2012

“The take away is that as long as prescriptions are written in good faith based upon an examination of the patient and if the doctor has established a legitimate medical purpose, there is no reason for concern,” says Lynch.

Diversion Occurs All Along Supply Chain

“Diversion can happen at so many places along the chain,” says Rusty Payne, a spokesman for the DEA drug diversion program in Washington, D.C. “People think it is just a doctor issue or a pharmacy issue, but it is that and much more.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Specific to the diversion of narcotics, it can take the form of patients who “doc shop,” pharmacy theft, and stolen prescription pads. Payne notes that around 70% of all abusers get their pills from friends or family.

He also stresses that the focus of the diversion project is not to stand between the patient and needed pain help. Much of their work involves inadequate record keeping and is dealt with administratively.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“It is important to understand that the laws are also there to protect the physician,” he notes. “We are law enforcers and do not get involved in legitimate doctor/patient relationships or decisions made about medical treatments.”

If physicians think there may be diversion problems occurring in their practice, they can contact the area DEA office and ask for the Office of Diversion Control. They can also visit www.deadiversion.usdoj.gov or call 1-800-882-9539.

Some of the signs of drug abuse and possible diversion of narcotics include:

  • Demanding immediate attention;
  • Having an unusually deep knowledge of controlled substances;
  • Frequently giving a medical history with textbook symptoms or a vague medical history;
  • Often will have no family doctor or health insurance;
  • Will often request a specific drug and is reluctant to take or says they have an allergy to other options;
  • Failing to keep appointments for further diagnostic tests or refusing to see another specialist;
  • Cutaneous signs of abuse such as track marks or related scars on the body;
  • Having to be seen right away, often near the end of or after normal office hours; and
  • Needing a replacement for a prescription that has been lost or stolen.2

Physician Interventions

Brian Daikh, MD, is a private practice physician with Rheumatology Associates in Portland, Maine. In his personal practice, he uses a patient contract to address diversion issues.

“With a contract, patients agree to get their pain medications from only one physician,” he says. “I also require that they use no nonprescription medications, such as marijuana or cocaine, and will drug test randomly if I suspect abuse. If there is evidence of a breach I would stop prescribing to them, and I have fired patients from my practice.”

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Drug UpdatesLegislation & AdvocacyProfessional Topics Tagged with:drugLegislationMedicareMedicationpharmaceuticalrheumatologistSafety

Related Articles

    2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News

    January 1, 2015

    Plus, hydrocodone combination products and brodalumab

    U.S. Lets More Healthcare Workers Prescribe Opioid Addiction Treatment

    January 24, 2018

    WASHINGTON (Reuters)—The U.S. Drug Enforcement Administration said on Tuesday it had changed a regulation to allow more healthcare professionals to prescribe a medication used to treat opioid addiction, opening up access in rural America where there are few doctors.1 Prior to 2000, only physicians could treat those with opioid addiction and had to register with…

    DEA Proposes Cutting Production of Come Opioids

    August 7, 2017

    (Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year. The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences